The next meeting of the All-Party Parliamentary Group (APPG) on M.E. will be the Annual General Meeting on Wednesday 10 May 2023 at 2pm. In addition to reconstituting the APPG, the AGM will include:
- a one year-on review of the implementation of the new NICE guideline including a presentation from Action for M.E. on the results from a Freedom of Information request regarding the implementation of the revised NICE Guideline responded to by 106 ICB’s and NHS Trusts.
- a discussion of support for those with severe ME
- consideration of our workplan for the coming year.
- Minutes of the AGM will be shared in accordance with APPG rules.
We'd be really grateful if you could invite your MP to attend. Your MP can get further information by emailing Carol Monaghan, MP (Chair of the APPG on M.E.).
Action for M.E. and The ME Association jointly share the secretariat responsibility for the APPG.
Contact your MP
Use this search engine to locate your MP's contact details: Find your MP – MPs and Lord's UK Parliament.
You can encourage your MP to attend by:
- Sharing social media announcements with your MP.
- Personalising the template email below.
Template email
Dear [YOUR MP'S NAME]
All-Party Parliamentary Group on M.E.
I am writing as one of your constituents to ask if you could attend the AGM of the APPG on M.E. between 2-3pm, on Wednesday 10th May 2023.
The group is chaired by Carol Monaghan, MP. Please contact her office for an invitation: carol.monaghan.mp@parliament.uk.
In addition to reconstituting the APPG, the AGM will include:
A one year-on review of the implementation of the new NICE guideline including a presentation from Action for M.E. on the results from a Freedom of Information request regarding the implementation of the revised NICE Guideline responded to by 106 ICB’s and NHS Trusts.
A discussion of support for those with severe ME.
Consideration of the APPG workplan for the coming year.
M.E. (Myalgic Encephalomyelitis) is a complex and long-term neurological condition that causes significant functional impairment and a lower quality of life than diabetes, multiple sclerosis, and even most cancers. It has been estimated to cost the UK economy over £3billion each year in healthcare, productivity losses, welfare benefits, and unpaid informal care.
While NICE has introduced a new guideline that will help to improve the clinical situation, M.E. would benefit greatly from biomedical research that can develop effective treatments.
M.E. is more prevalent than multiple sclerosis and affects many children and adults in your constituency.
[You can also include some additional information that relates to you as a person with M.E. living in this constituency and any issues you wish to raise regarding the two main agenda items – implementation of the new NICE guideline and the care and management of people with severe and very severe M.E.]
Yours sincerely
[ADD YOUR NAME and POSTAL ADDRESS]